Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
about
Clinical manufacturing of CAR T cells: foundation of a promising therapyRole of the tumor microenvironment in mature B-cell lymphoid malignanciesCD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsGene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and PerspectivesCurrent challenges and novel treatment strategies in double hit lymphomasChimeric Antigen Receptors Modified T-Cells for Cancer TherapyAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesNovel immunotherapies in lymphoid malignanciesImmunostimulatory Gene Therapy Using Oncolytic Viruses as VehiclesMesothelin-Targeted CARs: Driving T Cells to Solid TumorsLymphoma Immunotherapy: Current StatusCellular immunotherapy as a beacon of hope for hematological malignanciesCAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in LymphomaCAR T Cell Therapy: A Game Changer in Cancer TreatmentNovel immunotherapies for hematologic malignanciesUsing gene therapy to manipulate the immune system in the fight against B-cell leukemiasNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewNovel Drugs in Follicular LymphomaAdvances in Cancer Immunotherapy in Solid TumorsCD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic LeukaemiaT-cell receptor gene therapy--ready to go viral?CAR therapy: the CD19 paradigmCD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to DateManufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapiesSmart CARs engineered for cancer immunotherapyDesigning chimeric antigen receptors to effectively and safely target tumorsReengineering chimeric antigen receptor T cells for targeted therapy of autoimmune diseaseReappraising the timing of transplant for indolent non-Hodgkin lymphomas.Autologous lymphapheresis for the production of chimeric antigen receptor T cells.Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic MicePreserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Immunotherapy in hematologic malignancies: past, present, and future.Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8+ T cellsGenome-Edited T Cell Therapies.Engineering cord blood to improve engraftment after cord blood transplant.A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors.Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.Biology and clinical application of CAR T cells for B cell malignancies
P2860
Q26747037-ADC3E25C-759E-407B-8750-C87466C787CDQ26748775-791218B8-C585-48CF-9B6A-EC7956718D10Q26749139-84235283-8AE7-4DAB-B2FA-3290C38CC2FFQ26753082-C5422382-3B7A-4422-8776-575F36E66D85Q26769595-774C771B-6365-45DB-819C-F984139EBEE7Q26770385-44A63440-5F97-4762-9FAC-EC030F88EA31Q26773309-E0E3D4E4-21D6-4298-A4C4-203827CE3290Q26775720-71EDC992-9148-464A-8BB2-3BB4437A9F36Q26777394-67707613-3B78-45AF-B313-33B748444CF6Q26777403-7160621B-7D85-4F6A-9320-12B8A09320E7Q26778759-E29A23C8-D814-434A-BDE4-19E123F64A26Q26782902-B84EF84E-49A4-4099-B3D6-B447D2F6B3ACQ26784288-8E363399-0667-4C34-AD50-EC810A9A6156Q26800814-338C95F0-E948-4400-AFEA-8FAAD5E60247Q26822769-3FC1E7B4-8750-45E4-8FD8-F16B1069D99EQ27004436-68EE1530-AC45-499D-B7AE-68D4F85E9DCFQ27011297-AE437304-17CC-46BC-AA8C-C6BC27A42CFEQ27304386-E50BC1FE-6B92-415F-BC59-9D0D50430FC4Q28076335-9C813804-34D9-4E3A-8671-6879C5E35833Q28080113-1E13973E-7459-4087-9599-8A0A3C2729AFQ28081600-DF36E06C-448D-400C-929B-E5A07F9347C9Q28081611-6365AB90-9C4B-4B81-9630-F7AF67157447Q28081642-E277444E-ABB7-40CF-8526-21971B07F265Q28083296-3657AA25-AA03-48D3-9C86-A4ACFC2E8F6EQ28085769-B37EDA61-71D4-4FE8-9BF4-90B8DFA7DA9BQ28087236-023AF638-7BFB-44BD-BC5C-F8C1257F1F8EQ28088526-E8F40A47-0D11-46D9-80FA-9C446B959D25Q28276800-219B4329-D4EE-41F8-8BFF-1F27A9FF18D9Q30248407-3243016F-618F-4664-815A-D7FB7795064AQ30253090-AABDA2C7-A5DF-45AF-AE2C-A53700896EECQ30399332-76D232F9-325D-4B41-B307-DA1ABB06116AQ30764873-D4D98D94-ACBF-4BA2-91B3-406F29583A73Q33593865-D948E25A-E8BE-4F31-B18D-A965AF896E3FQ33686036-3EEF070A-E2CD-4C62-9563-F5847CC1A56AQ33729598-45ADC62D-BFF2-4DBC-AF06-20A25264FD9DQ33766995-FA6D63C0-9177-40F9-9680-D2DF60725F75Q33803754-81B7C550-3F73-45AF-8B6F-29FD8FD16F39Q33823270-F81FE85A-4CEC-431F-9893-8D1A0D634BE6Q33851168-0EC9D040-F234-4513-918C-DD00A4AA9C91Q33907565-250C0133-A312-4EF9-9AC6-1EA5F93C9DC2
P2860
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.
@ast
Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.
@en
Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.
@nl
type
label
Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.
@ast
Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.
@en
Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.
@nl
prefLabel
Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.
@ast
Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.
@en
Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.
@nl
P2093
P2860
P356
P1476
Chemotherapy-refractory diffus ...... D19 chimeric antigen receptor.
@en
P2093
Avindra Nath
Clara C Chen
David E Spaner
Debbie-Ann N Nathan
Giao Q Phan
James C Yang
James N Kochenderfer
Kathleen E Morton
Lien T Ngo
P2860
P304
P356
10.1200/JCO.2014.56.2025
P407
P577
2014-08-25T00:00:00Z